Other substances

Eribulin mesylate

A microtubule-destabilising agent.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
4
 AI-suggested references
0
 Clinical trials

General information

Eribulin mesylate on PubChem

Synonyms

Eribulin

Marketed as

HALAVEN

 

Structure image - Eribulin mesylate

C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O.CS(=O)(=O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors
3CLpro Small molecule In silico 		in silico 3.27

Predicted to inhibit SARS-CoV-2 3C-like protease.

 Feb/10/2021

AI-suggested references

Link Publication date
A systematic drug repurposing approach to identify promising inhibitors from FDA-approved drugs against Nsp4 protein of SARS-CoV-2.
Nov/30/2021
Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies.
Sep/20/2021
Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells.
Apr/12/2021
Unravelling the therapeutic potential of marine drugs as SARS-CoV-2 inhibitors: An insight from essential dynamics and free energy landscape.
May/29/2021
Export (.csv)